0.6744  -0.004 (-0.59%)		04-17 16:00
Open: 0.66 High: 0.6863 Volume: 59,507		Pre. Close: 0.6784 Low: 0.651 Market Cap: 18(M)

Short term
Mid term
Targets	6-month :	0.87	1-year :	0.98
Resists	First :	0.74	Second :	0.84
Pivot price	0.72
Supports	First :	0.6	Second :	0.49
MAs	MA(5) :	0.68	MA(20) :	0.73
	MA(100) :	0.69	MA(250) :	1.2
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	34.2	D(3) :	35.4
RSI	RSI(14): 41
52-week	High :	3.7	Low :	0.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GLTO ] has closed above bottom band by 17.1%. Bollinger Bands are 0% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.69 - 0.69	0.69 - 0.69
Low:	0.64 - 0.65	0.65 - 0.65
Close:	0.67 - 0.68	0.68 - 0.68

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Mon, 25 Mar 2024
GLTO Stock Quote Price and Forecast - CNN

Wed, 14 Feb 2024
New Strong Buy Stocks for February 14th - Zacks Investment Research

Wed, 14 Feb 2024
New Strong Buy Stocks for February 14th - Yahoo Finance

Wed, 14 Feb 2024
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Wed, 10 Jan 2024
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? - Simply Wall St

Tue, 09 Jan 2024
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	27 (M)
Shares Float	22 (M)
Held by Insiders	11.8 (%)
Held by Institutions	19.7 (%)
Shares Short	32 (K)
Shares Short P.Month	55 (K)

EPS	-1.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.19
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-41 %
Return on Equity (ttm)	-81.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.34
Qtrly Earnings Growth	0 %
Operating Cash Flow	-37 (M)
Levered Free Cash Flow	-21 (M)

PE Ratio	-0.47
PEG Ratio	-0.1
Price to Book value	0.56
Price to Sales	0
Price to Cash Flow	-0.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.